Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster, Cardiol, Münster, Germany.
J Nephrol. 2021 Jun;34(3):811-820. doi: 10.1007/s40620-020-00909-8. Epub 2021 Feb 8.
Post-contrast acute kidney injury (AKI) is a dreaded complication of endovascular revascularization using iodinated contrast medium in patients with peripheral artery disease and concomitant chronic kidney disease (CKD). This study sought to evaluate the incidence of AKI in patients with peripheral artery disease and CKD undergoing endovascular revascularization and using carbon dioxide (CO) as contrast medium.
From 04/2015 to 07/2018, all consecutive peripheral artery disease patients with CKD stage ≥ 3 referred for endovascular revascularization of symptomatic peripheral artery disease were prospectively included. During endovascular revascularization, CO as contrast medium was manually injected and iodinated contrast medium was additionally used when needed. The reference group consisted of 211 cardiovascular risk factor-matched patients undergoing endovascular revascularization with iodinated contrast medium only. CO-guided endovascular revascularization was performed in 102 patients, thereof 16 (15.7%) patients exclusively with CO. Baseline CKD stage ≥ 4 and iodinated contrast medium volume > 50 ml were disproportionally associated with post-procedural post-contrast AKI. At CKD stage 4 the odds ratio for post-contrast AKI was 13.2 (95% CI 1.489-117.004; p = 0.02) for iodinated contrast medium volume 51-100 ml and 37.7 (95% CI 3.927-362.234; p = 0.002) for iodinated contrast medium volume > 100 ml. The corresponding values at CKD stage 5 were 23.7 (95% CI 2.666-210.583; p = 0.005) and 28.3 (95% CI 3.289-243.252; p = 0.002), respectively. Radiation (dose area product) was significantly higher in the CO-endovascular revascularization group (6.025 ± 6.926 cGycm vs. 4.281 ± 4.722 cGycm, p = 0.009).
CO is an applicable and safe alternative to iodinated contrast medium for endovascular revascularization in peripheral artery disease patients with concomitant CKD. Patients with CKD stage 4 or 5, being at highest risk for post-contrast AKI, should primarily be treated by CO-guided endovascular revascularization.
碘造影剂在伴有慢性肾脏病(CKD)的外周动脉疾病患者的血管内血运重建中引起的急性肾损伤(AKI)是一种可怕的并发症。本研究旨在评估二氧化碳(CO)作为造影剂在外周动脉疾病和 CKD 患者血管内血运重建中的应用,以评估其发生 AKI 的发生率。
从 2015 年 4 月至 2018 年 7 月,所有因症状性外周动脉疾病而接受血管内血运重建的连续 CKD 期≥3 期的外周动脉疾病患者均前瞻性纳入研究。在血管内血运重建期间,手动注入 CO 作为造影剂,当需要时,再额外使用碘造影剂。参考组由 211 名心血管危险因素匹配的患者组成,他们仅接受碘造影剂进行血管内血运重建。102 名患者接受 CO 引导的血管内血运重建,其中 16 名(15.7%)患者仅接受 CO 治疗。基线 CKD 期≥4 期和碘造影剂用量>50ml 与术后对比后 AKI 不成比例相关。在 CKD 期 4 时,碘造影剂用量 51-100ml 的对比后 AKI 的比值比为 13.2(95%CI 1.489-117.004;p=0.02),碘造影剂用量>100ml 的比值比为 37.7(95%CI 3.927-362.234;p=0.002)。在 CKD 期 5 时,相应值分别为 23.7(95%CI 2.666-210.583;p=0.005)和 28.3(95%CI 3.289-243.252;p=0.002)。CO 血管内血运重建组的辐射(剂量面积乘积)明显更高(6.025±6.926cGycm 与 4.281±4.722cGycm,p=0.009)。
CO 是碘造影剂在伴有 CKD 的外周动脉疾病患者血管内血运重建中的一种可行且安全的替代物。CKD 期 4 或 5 期的患者,对比后 AKI 风险最高,应优先采用 CO 引导的血管内血运重建治疗。